|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
HART was incorporated on May 3, 2012 by Harvard Bioscience to provide a clinical-stage regenerative medicine company developing life-saving medical devices. Harvard Bioscience has been designing and manufacturing devices for life science researchers for over 100 years. HART was first established in 2007 to explore the regenerative medicine market and determine if the company’s expertise and commitment to leading edge technology could be applied to treating unmet critical medical needs. HART has grown to become the recognized leader in providing scaffolds, bioreactors and other tools for synthetic tracheas. The company is uniquely positioned to develop advanced instrumentation to accelerate regenerative medicine, tissue engineering and cell therapy experimentation. Our corporate headquarters are in the Boston area allowing us to develop relationships with world renown universities, hospitals and one of the leading worldwide biotechnology clusters. We also have leveraged these relationships to work with leading researchers, clinicians and centers across the world. We believe combining our commitment to patients with clinical and research relationships will allow us to drive the basic technology developed in the initial organs and expand into work on other critical disease states that effect solid organs.
Harvard Apparatus Regenerative Technology (HART) is now Biostage.
|© 2022 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|